Loading...
XLONTSTL
Market cap255mUSD
Jan 07, Last price  
430.00GBP
1D
-1.15%
1Q
16.22%
Jan 2017
175.64%
IPO
861.71%
Name

Tristel PLC

Chart & Performance

D1W1MN
XLON:TSTL chart
P/E
3,160.36
P/S
489.06
EPS
0.14
Div Yield, %
0.03%
Shrs. gr., 5y
1.02%
Rev. gr., 5y
9.89%
Revenues
42m
+16.45%
3,009,0003,746,0005,148,0005,961,0006,847,0008,764,0009,287,00010,939,00010,558,00013,470,00015,334,00017,104,00020,273,00022,220,00026,169,00031,678,00030,998,00031,123,00036,009,00041,933,000
Net income
6m
+45.46%
39,000506,000551,0001,049,000919,0001,215,000476,000707,000-1,264,0001,298,0002,215,0002,102,0003,417,0003,272,0004,031,0005,100,0003,656,000987,0004,461,0006,489,000
CFO
11m
+31.88%
269,000322,0001,113,000535,000948,0001,235,000-30,0001,499,000709,0003,271,0002,612,0004,550,0004,352,0004,495,0005,486,0006,989,0006,478,0005,553,0008,490,00011,197,000
Dividend
Mar 21, 20245.24 GBP/sh

Profile

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand; contamination control products, which include cleanroom, laboratory, pharmaceutical, cosmetic, and toiletry disinfectants under the Crystel brand; and airborne and veterinary device disinfectants under the Anistel brand. The company was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
URL
https://tristel.com/hk-en/
IPO date
Jun 01, 2005
Employees
194
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
41,933
16.45%
36,009
15.70%
31,123
0.40%
Cost of revenue
34,176
27,747
24,685
Unusual Expense (Income)
NOPBT
7,757
8,262
6,438
NOPBT Margin
18.50%
22.94%
20.69%
Operating Taxes
593
651
568
Tax Rate
7.64%
7.88%
8.82%
NOPAT
7,164
7,611
5,870
Net income
6,489
45.46%
4,461
351.98%
987
-73.00%
Dividends
(6,224)
(4,511)
(3,091)
Dividend yield
2.84%
2.68%
1.84%
Proceeds from repurchase of equity
676
193
398
BB yield
-0.31%
-0.11%
-0.24%
Debt
Debt current
1,034
859
814
Long-term debt
10,694
9,501
10,808
Deferred revenue
(599)
(720)
Other long-term liabilities
599
720
Net debt
(61)
3,988
5,984
Cash flow
Cash from operating activities
11,197
8,490
5,553
CAPEX
(2,182)
(2,423)
(1,203)
Cash from investing activities
(5,400)
(4,845)
(1,202)
Cash from financing activities
(6,570)
(5,444)
(3,623)
FCF
5,687
13,381
(692)
Balance
Cash
11,789
9,545
8,883
Long term investments
(3,173)
(3,245)
Excess cash
9,692
4,572
4,082
Stockholders' equity
18,124
14,570
12,851
Invested Capital
28,582
31,189
30,384
ROIC
23.97%
24.72%
18.33%
ROCE
20.12%
22.72%
18.30%
EV
Common stock shares outstanding
47,844
47,358
47,769
Price
4.58
28.87%
3.55
0.71%
3.53
-44.75%
Market cap
218,886
30.20%
168,121
-0.16%
168,386
-43.88%
EV
218,825
172,395
174,442
EBITDA
10,463
10,812
9,148
EV/EBITDA
20.91
15.94
19.07
Interest
218
179
195
Interest/NOPBT
2.81%
2.17%
3.03%